Loading
NP137 is a monoclonal antibody from NETRIS Pharma, in registered phase 2 trials for endometrial cancer, cervical cancer.
NP137 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by NETRIS Pharma, in endometrial cancer, cervical cancer. A monoclonal antibody, as described in the registry record. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
A monoclonal antibody, as described in the registry record.
1.NP137 binds its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"NP137" OR ABSTRACT:"NP137") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NP137, not a curated reading list.
Shares Endometrial cancer, Cervical cancer and the tags pipeline, registry-only.
Shares Endometrial cancer and the tags pipeline, registry-only.
Shares Cervical cancer and the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.